Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTBVAC Phase I in Healthy Indian Adults
NCT06438978Phase 1Completed
- Sponsor
- Bharat Biotech
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mtbvac in Tuberculosis (TB), sponsored by Bharat Biotech. Primary endpoints: Immediate adverse events at 30 months, Solicited adverse events at 14 days and 6 more. Started Jan 2024; status: completed.
02
Drugs
mtbvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06438978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438978.